Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 4:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–36 of 36 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants

NCT05515601
Conditions
Healthy
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
396 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Cypress, California • Daytona Beach, Florida • Dilworth, Minnesota + 3 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Formulations of LY3074828 in Healthy Participants

NCT03662100
Conditions
Healthy
Interventions
LY3074828, LY3074828, Auto-injector (AI), Prefilled syringe (PFS)
Biological · Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 11 more
Conditions
Ulcerative Colitis
Interventions
LY4268989, Mirikizumab, LY4268989 Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
40
States / cities
Scottsdale, Arizona • Anaheim, California • Lancaster, California + 36 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants

NCT05644353
Conditions
Healthy
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Cypress, California • Daytona Beach, Florida • Miami, Florida + 2 more
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 19 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
11
States / cities
San Francisco, California • Hartford, Connecticut • Atlanta, Georgia + 7 more
Conditions
Crohn's Disease, Obesity or Overweight
Interventions
Mirikizumab, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Dothan, Alabama • Anaheim, California • Beverly Hills, California + 29 more
Conditions
Crohn's Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 9 more
Conditions
Ulcerative Colitis, Obesity or Overweight
Interventions
Mirikizumab, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
Dothan, Alabama • Anaheim, California • Beverly Hills, California + 30 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Injections of LY3074828 in Healthy Participants

NCT03886948
Conditions
Healthy
Interventions
LY3074828, Pre-filled syringe (PFS), Autoinjector (AI)
Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Conditions
Crohn's Disease
Interventions
Mirikizumab, Ustekinumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
15 Years to 80 Years
Enrollment
1,158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
140
States / cities
Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 113 more
Conditions
Ulcerative Colitis
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Orange, California • San Francisco, California • Denver, Colorado + 18 more